Advertisement
Advances in Clinical Radiology

Advances in Head and Neck Paraganglioma Imaging

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Advances in Clinical Radiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lowe J.S.
        Fifth edition. Stevens & Lowe’s human histology. viii. Elsevier, Philadelphia2020: 426
        • Iturriaga R.
        • Alcayaga J.
        • Chapleau M.W.
        • et al.
        Carotid body chemoreceptors: physiology, pathology, and implications for health and disease.
        Physiol Rev. 2021; 101: 1177-1235
        • Rao A.B.
        • Koeller K.K.
        • Adair C.F.
        From the archives of the AFIP. Paragangliomas of the head and neck: radiologic-pathologic correlation. Armed Forces Institute of Pathology.
        Radiographics. 1999; 19: 1605-1632
        • Glenner G.G.
        • Grimley P.M.
        Tumors of the extra-adrenal paraganglion system (including chemoreceptors). Atlas of tumor pathology.
        Armed Forces Institute of Pathology, 1974: 90 (for sale by the American Registry of Pathology, Armed Forces Institute of Pathology)
        • Borba L.A.
        • Al-Mefty O.
        Intravagal paragangliomas: report of four cases.
        Neurosurgery. 1996; 38 ([discussion: 575]): 569-575
        • Smith J.D.
        • Harvey R.N.
        • Darr O.A.
        • et al.
        Head and neck paragangliomas: a two-decade institutional experience and algorithm for management.
        Laryngoscope Investig Otolaryngol. 2017; 2: 380-389
        • Singh S.
        • Madan R.
        • Singh M.K.
        • et al.
        Head-and-neck paragangliomas: an overview of 54 cases operated at a tertiary care center.
        South Asian J Cancer. 2019; 8: 237-240
        • Saldana M.J.
        • Salem L.E.
        • Travezan R.
        High altitude hypoxia and chemodectomas.
        Hum Pathol. 1973; 4: 251-263
        • Buffet A.
        • Ben Aim L.
        • Leboulleux S.
        • et al.
        Positive impact of genetic test on the management and outcome of patients with paraganglioma and/or pheochromocytoma.
        J Clin Endocrinol Metab. 2019; 104: 1109-1118
        • Suri A.K.
        • Fleysher R.
        • Lipton M.L.
        Subject based registration for individualized analysis of diffusion tensor MRI.
        PLoS One. 2015; 10: e0142288
        • Lam A.K.
        Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours.
        Endocr Pathol. 2017; 28: 213-227
        • Lee J.H.
        • Barich F.
        • Karnell L.H.
        • et al.
        National Cancer Data Base report on malignant paragangliomas of the head and neck.
        Cancer. 2002; 94: 730-737
        • Koopman K.
        • Gaal J.
        • de Krijger R.R.
        Pheochromocytomas and paragangliomas: new developments with regard to classification, genetics, and cell of origin.
        Cancers (Basel). 2019; 11: 1070
        • Kimura N.
        • Takayanagi R.
        • Takizawa N.
        • et al.
        Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma.
        Endocr Relat Cancer. 2014; 21: 405-414
        • Moskovic D.J.
        • Smolarz J.R.
        • Stanley D.
        • et al.
        Malignant head and neck paragangliomas: is there an optimal treatment strategy?.
        Head Neck Oncol. 2010; 2: 23
        • Westerband A.
        • Hunter G.C.
        • Cintora I.
        • et al.
        Current trends in the detection and management of carotid body tumors.
        J Vasc Surg. 1998; 28 ([discussion: 92-3]): 84-92
        • Moore M.G.
        • Netterville J.L.
        • Mendenhall W.M.
        • et al.
        Head and neck paragangliomas: an update on evaluation and management.
        Otolaryngol Head Neck Surg. 2016; 154: 597-605
        • Fishbein L.
        • Leshchiner I.
        • Walter V.
        • et al.
        Comprehensive molecular characterization of pheochromocytoma and paraganglioma.
        Cancer Cell. 2017; 31: 181-193
        • Nolting S.
        • Ullrich M.
        • Pietzsch J.
        • et al.
        Current management of pheochromocytoma/paraganglioma: a guide for the practicing clinician in the Era of precision medicine.
        Cancers (Basel). 2019; 11: 1505
        • Garcia-Carbonero R.
        • Matute Teresa F.
        • Mercader-Cidoncha E.
        • et al.
        Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas.
        Clin Transl Oncol. 2021; 23: 1995-2019
        • Lenders J.W.
        • Duh Q.Y.
        • Eisenhofer G.
        • et al.
        Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline.
        J Clin Endocrinol Metab. 2014; 99: 1915-1942
        • Crona J.
        • Taieb D.
        • Pacak K.
        New perspectives on pheochromocytoma and paraganglioma: toward a molecular classification.
        Endocr Rev. 2017; 38: 489-515
        • Majewska A.
        • Budny B.
        • Ziemnicka K.
        • et al.
        Head and neck paragangliomas-A genetic overview.
        Int J Mol Sci. 2020; 21: 7669
        • Nolting S.
        • Bechmann N.
        • Taieb D.
        • et al.
        Personalized management of pheochromocytoma and paraganglioma.
        Endocr Rev. 2021; https://doi.org/10.1210/endrev/bnab019
        • Hescot S.
        • Curras-Freixes M.
        • Deutschbein T.
        • et al.
        Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-Prono Study): a european network for the study of adrenal tumors retrospective study.
        J Clin Endocrinol Metab. 2019; 104: 2367-2374
        • Pasini B.
        • Stratakis C.A.
        SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes.
        J Intern Med. 2009; 266: 19-42
        • Olsen W.L.
        • Dillon W.P.
        • Kelly W.M.
        • et al.
        MR imaging of paragangliomas.
        AJR Am J Roentgenol. 1987; 148: 201-204
        • van Gils A.P.
        • van den Berg R.
        • Falke T.H.
        • et al.
        MR diagnosis of paraganglioma of the head and neck: value of contrast enhancement.
        AJR Am J Roentgenol. 1994; 162: 147-153
        • Vogl T.J.
        • Juergens M.
        • Balzer J.O.
        • et al.
        Glomus tumors of the skull base: combined use of MR angiography and spin-echo imaging.
        Radiology. 1994; 192: 103-110
        • Som P.M.
        • Braun I.F.
        • Shapiro M.D.
        • et al.
        Tumors of the parapharyngeal space and upper neck: MR imaging characteristics.
        Radiology. 1987; 164: 823-829
        • Newton T.H.
        • Potts D.G.
        Angiography. Radiology of the skull and brain, v 2.
        Mosby, St. Louis1974
        • Skolnik A.D.
        • Loevner L.A.
        • Sampathu D.M.
        • et al.
        Cranial nerve schwannomas: diagnostic imaging approach.
        Radiographics. 2016; 36: 1463-1477
        • Furukawa M.
        • Parvathaneni U.
        • Maravilla K.
        • et al.
        Dynamic contrast-enhanced MR perfusion imaging of head and neck tumors at 3 Tesla.
        Head Neck. 2013; 35: 923-929
        • Klionsky D.J.
        • Abdalla F.C.
        • Abeliovich H.
        • et al.
        Guidelines for the use and interpretation of assays for monitoring autophagy.
        Autophagy. 2012; 8: 445-544
        • Yuan Y.
        • Shi H.
        • Tao X.
        Head and neck paragangliomas: diffusion weighted and dynamic contrast enhanced magnetic resonance imaging characteristics.
        BMC Med Imaging. 2016; 16: 12
        • Gaddikeri S.
        • Hippe D.S.
        • Anzai Y.
        Dynamic contrast-enhanced MRI in the evaluation of carotid space paraganglioma versus schwannoma.
        J Neuroimaging. 2016; 26: 618-625
        • Malla S.R.
        • Bhalla A.S.
        • Manchanda S.
        • et al.
        Dynamic contrast-enhanced magnetic resonance imaging for differentiating head and neck paraganglioma and schwannoma.
        Head Neck. 2021; 43: 2611-2622
        • Ota Y.
        • Liao E.
        • Capizzano A.A.
        • et al.
        Diagnostic role of diffusion-weighted and dynamic contrast-enhanced perfusion MR imaging in paragangliomas and schwannomas in the head and neck.
        AJNR Am J Neuroradiol. 2021; 42: 1839-1846
        • Arnold S.M.
        • Strecker R.
        • Scheffler K.
        • et al.
        Dynamic contrast enhancement of paragangliomas of the head and neck: evaluation with time-resolved 2D MR projection angiography.
        Eur Radiol. 2003; 13: 1608-1611
        • Ferre J.C.
        • Brunet J.F.
        • Carsin-Nicol B.
        • et al.
        Optimized time-resolved 3D contrast-enhanced MRA at 3T: appreciating the feasibility of assessing cervical paragangliomas.
        J Neuroradiol. 2010; 37: 104-108
        • Sakai M.
        • Illies T.
        • Jerusel N.
        • et al.
        Feasibility of non-contrast-enhanced four dimensional (4D) MRA in head and neck tumors, comparison with contrast-enhanced 4D MRA.
        Springerplus. 2016; 5: 1282
        • Arsovic E.
        • Montava M.
        • Fakhry N.
        • et al.
        Quantitative biomarkers allow the diagnosis of head and neck paraganglioma on multiparametric MRI.
        Eur J Radiol. 2021; 143: 109911
        • Aschenbach R.
        • Basche S.
        • Vogl T.J.
        • et al.
        Diffusion-weighted imaging and ADC mapping of head-and-neck paragangliomas: initial experience.
        Klin Neuroradiol. 2009; 19: 215-219
        • Ota Y.
        • Naganawa S.
        • Kurokawa R.
        • et al.
        Assessment of MR imaging and CT in differentiating hereditary and nonhereditary paragangliomas.
        AJNR Am J Neuroradiol. 2021; 42: 1320-1326
        • Ardekani B.A.
        • Guckemus S.
        • Bachman A.
        • et al.
        Quantitative comparison of algorithms for inter-subject registration of 3D volumetric brain MRI scans. Comparative Study.
        J Neurosci Methods. 2005; 142: 67-76
        • Neves F.
        • Huwart L.
        • Jourdan G.
        • et al.
        Head and neck paragangliomas: value of contrast-enhanced 3D MR angiography.
        AJNR Am J Neuroradiol. 2008; 29: 883-889
        • Gravel G.
        • Niccoli P.
        • Rohmer V.
        • et al.
        The value of a rapid contrast-enhanced angio-MRI protocol in the detection of head and neck paragangliomas in SDHx mutations carriers: a retrospective study on behalf of the PGL.EVA investigators.
        Eur Radiol. 2016; 26: 1696-1704
        • Tufton N.
        • White G.
        • Drake W.M.
        • et al.
        Diffusion-weighted imaging (DWI) highlights SDHB-related tumours: a pilot study.
        Clin Endocrinol (Oxf). 2019; 91: 104-109
        • Varoquaux A.
        • le Fur Y.
        • Imperiale A.
        • et al.
        Magnetic resonance spectroscopy of paragangliomas: new insights into in vivo metabolomics.
        Endocr Relat Cancer. 2015; 22: M1-M8
        • Casey R.T.
        • McLean M.A.
        • Madhu B.
        • et al.
        Translating in vivo metabolomic analysis of succinate dehydrogenase deficient tumours into clinical utility.
        JCO Precis Oncol. 2018; 2: 1-12
        • Lussey-Lepoutre C.
        • Bellucci A.
        • Burnichon N.
        • et al.
        Succinate detection using in vivo (1)H-MR spectroscopy identifies germline and somatic SDHx mutations in paragangliomas.
        Eur J Nucl Med Mol Imaging. 2020; 47: 1510-1517
        • Taieb D.
        • Hicks R.J.
        • Hindie E.
        • et al.
        European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma.
        Eur J Nucl Med Mol Imaging. 2019; 46: 2112-2137
        • Winzeler B.
        • Challis B.G.
        • Casey R.T.
        Precision medicine in phaeochromocytoma and paraganglioma.
        J Pers Med. 2021; 11https://doi.org/10.3390/jpm11111239
        • Castinetti F.
        • Kroiss A.
        • Kumar R.
        • et al.
        15 YEARS OF PARAGANGLIOMA: imaging and imaging-based treatment of pheochromocytoma and paraganglioma.
        Endocr Relat Cancer. 2015; 22: T135-T145
        • Timmers H.J.
        • Chen C.C.
        • Carrasquillo J.A.
        • et al.
        Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.
        J Clin Endocrinol Metab. 2009; 94: 4757-4767
        • Fonte J.S.
        • Robles J.F.
        • Chen C.C.
        • et al.
        False-negative (1)(2)(3)I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease.
        Endocr Relat Cancer. 2012; 19: 83-93
        • Plouin P.F.
        • Amar L.
        • Dekkers O.M.
        • et al.
        European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma.
        Eur J Endocrinol. 2016; 174: G1-G10
        • Taieb D.
        • Jha A.
        • Treglia G.
        • et al.
        Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups.
        Endocr Relat Cancer. 2019; 26: R627-R652
        • Scalise M.
        • Galluccio M.
        • Console L.
        • et al.
        The Human SLC7A5 (LAT1): the Intriguing Histidine/Large Neutral Amino Acid Transporter and Its Relevance to Human Health.
        Front Chem. 2018; 6: 243
        • Carrasquillo J.A.
        • Chen C.C.
        • Jha A.
        • et al.
        Imaging of Pheochromocytoma and Paraganglioma.
        J Nucl Med. 2021; 62: 1033-1042
        • Timmers H.J.
        • Taieb D.
        • Pacak K.
        Current and future anatomical and functional imaging approaches to pheochromocytoma and paraganglioma.
        Horm Metab Res. 2012; 44: 367-372
        • Chang C.A.
        • Pattison D.A.
        • Tothill R.W.
        • et al.
        68)Ga-DOTATATE and (18)F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity.
        Cancer Imaging. 2016; 16: 22
        • Taieb D.
        • Sebag F.
        • Barlier A.
        • et al.
        18F-FDG avidity of pheochromocytomas and paragangliomas: a new molecular imaging signature?.
        J Nucl Med. 2009; 50: 711-717
        • Han S.
        • Suh C.H.
        • Woo S.
        • et al.
        Performance of (68)Ga-DOTA-conjugated somatostatin receptor-targeting peptide pet in detection of pheochromocytoma and paraganglioma: a systematic review and metaanalysis.
        J Nucl Med. 2019; 60: 369-376
        • Elston M.S.
        • Meyer-Rochow G.Y.
        • Conaglen H.M.
        • et al.
        Increased SSTR2A and SSTR3 expression in succinate dehydrogenase-deficient pheochromocytomas and paragangliomas.
        Hum Pathol. 2015; 46: 390-396
        • Kan Y.
        • Zhang S.
        • Wang W.
        • et al.
        68)Ga-somatostatin receptor analogs and (18)F-FDG PET/CT in the localization of metastatic pheochromocytomas and paragangliomas with germline mutations: a meta-analysis.
        Acta Radiol. 2018; 59: 1466-1474
        • Janssen I.
        • Chen C.C.
        • Taieb D.
        • et al.
        68Ga-DOTATATE PET/CT in the localization of head and neck paragangliomas compared with other functional imaging modalities and CT/MRI.
        J Nucl Med. 2016; 57: 186-191
        • Withey S.J.
        • Perrio S.
        • Christodoulou D.
        • et al.
        Imaging features of succinate dehydrogenase-deficient pheochromocytoma-paraganglioma syndromes.
        Radiographics. 2019; 39: 1393-1410
        • Shamblin W.R.
        • ReMine W.H.
        • Sheps S.G.
        • et al.
        Carotid body tumor (chemodectoma). Clinicopathologic analysis of ninety cases.
        Am J Surg. 1971; 122: 732-739
        • Lim J.Y.
        • Kim J.
        • Kim S.H.
        • et al.
        Surgical treatment of carotid body paragangliomas: outcomes and complications according to the shamblin classification.
        Clin Exp Otorhinolaryngol. 2010; 3: 91-95
        • Arya S.
        • Rao V.
        • Juvekar S.
        • et al.
        Carotid body tumors: objective criteria to predict the Shamblin group on MR imaging.
        AJNR Am J Neuroradiol. 2008; 29: 1349-1354
        • Papaspyrou K.
        • Mewes T.
        • Rossmann H.
        • et al.
        Head and neck paragangliomas: report of 175 patients (1989-2010).
        Head Neck. 2012; 34: 632-637
        • Netterville J.L.
        • Jackson C.G.
        • Miller F.R.
        • et al.
        Vagal paraganglioma: a review of 46 patients treated during a 20-year period.
        Arch Otolaryngol Head Neck Surg. 1998; 124: 1133-1140
        • Ivan M.E.
        • Sughrue M.E.
        • Clark A.J.
        • et al.
        A meta-analysis of tumor control rates and treatment-related morbidity for patients with glomus jugulare tumors.
        J Neurosurg. 2011; 114: 1299-1305
        • Prasad S.C.
        • Mimoune H.A.
        • D'Orazio F.
        • et al.
        The role of wait-and-scan and the efficacy of radiotherapy in the treatment of temporal bone paragangliomas.
        Otol Neurotol. 2014; 35: 922-931
        • Litle V.R.
        • Reilly L.M.
        • Ramos T.K.
        Preoperative embolization of carotid body tumors: when is it appropriate?.
        Ann Vasc Surg. 1996; 10: 464-468
        • Power A.H.
        • Bower T.C.
        • Kasperbauer J.
        • et al.
        Impact of preoperative embolization on outcomes of carotid body tumor resections.
        J Vasc Surg. 2012; 56: 979-989
        • Gaynor B.G.
        • Elhammady M.S.
        • Jethanamest D.
        • et al.
        Incidence of cranial nerve palsy after preoperative embolization of glomus jugulare tumors using Onyx.
        J Neurosurg. 2014; 120: 377-381
        • Lightowlers S.
        • Benedict S.
        • Jefferies S.J.
        • et al.
        Excellent local control of paraganglioma in the head and neck with fractionated radiotherapy.
        Clin Oncol (R Coll Radiol. 2010; 22: 382-389
        • Suarez C.
        • Rodrigo J.P.
        • Bodeker C.C.
        • et al.
        Jugular and vagal paragangliomas: systematic study of management with surgery and radiotherapy.
        Head Neck. 2013; 35: 1195-1204
        • Sniezek J.C.
        • Netterville J.L.
        • Sabri A.N.
        Vagal paragangliomas.
        Otolaryngol Clin N Am. 2001; 34 (vi): 925-939
        • Pollock B.E.
        Stereotactic radiosurgery in patients with glomus jugulare tumors.
        Neurosurg Focus. 2004; 17: E10
        • Langerman A.
        • Athavale S.M.
        • Rangarajan S.V.
        • et al.
        Natural history of cervical paragangliomas: outcomes of observation of 43 patients.
        Arch Otolaryngol Head Neck Surg. 2012; 138: 341-345
        • Carlson M.L.
        • Sweeney A.D.
        • Wanna G.B.
        • et al.
        Natural history of glomus jugulare: a review of 16 tumors managed with primary observation.
        Otolaryngol Head Neck Surg. 2015; 152: 98-105
        • Jansen J.C.
        • van den Berg R.
        • Kuiper A.
        • et al.
        Estimation of growth rate in patients with head and neck paragangliomas influences the treatment proposal.
        Cancer. 2000; 88: 2811-2816
        • Pryma D.A.
        • Chin B.B.
        • Noto R.B.
        • et al.
        Efficacy and safety of high-specific-activity (131)I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma.
        J Nucl Med. 2019; 60: 623-630
        • Kolasinska-Cwikla A.
        • Peczkowska M.
        • Cwikla J.B.
        • et al.
        A clinical efficacy of PRRT in Patients With advanced, nonresectable, paraganglioma-pheochromocytoma, related to SDHx gene mutation.
        J Clin Med. 2019; 8: 952
        • Satapathy S.
        • Mittal B.R.
        • Bhansali A.
        Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: a systematic review and meta-analysis.
        Clin Endocrinol (Oxf). 2019; 91: 718-727
        • Severi S.
        • Bongiovanni A.
        • Ferrara M.
        • et al.
        Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials.
        ESMO Open. 2021; 6: 100171
        • Estevao R.
        • Duarte H.
        • Lopes F.
        • et al.
        Peptide receptor radionuclide therapy in head and neck paragangliomas - Report of 14 cases.
        Rev Laryngol Otol Rhinol (Bord). 2015; 136: 155-158
        • Puranik A.D.
        • Kulkarni H.R.
        • Singh A.
        • et al.
        Peptide receptor radionuclide therapy with (90)Y/(177)Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours).
        Eur J Nucl Med Mol Imaging. 2015; 42: 1223-1230
        • Niemeijer N.D.
        • Alblas G.
        • van Hulsteijn L.T.
        • et al.
        Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis.
        Clin Endocrinol (Oxf). 2014; 81: 642-651
        • Tena I.
        • Gupta G.
        • Tajahuerce M.
        • et al.
        Successful second-line metronomic temozolomide in metastatic paraganglioma: case reports and review of the literature.
        Clin Med Insights Oncol. 2018; 12
        • van der Tuin K.
        • Mensenkamp A.R.
        • Tops C.M.J.
        • et al.
        Clinical aspects of SDHA-related pheochromocytoma and paraganglioma: a nationwide study.
        J Clin Endocrinol Metab. 2018; 103: 438-445
        • Burnichon N.
        • Rohmer V.
        • Amar L.
        • et al.
        The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas.
        J Clin Endocrinol Metab. 2009; 94: 2817-2827
        • Buffet A.
        • Burnichon N.
        • Favier J.
        • et al.
        An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma.
        Best Pract Res Clin Endocrinol Metab. 2020; 34: 101416
        • Kunst H.P.
        • Rutten M.H.
        • de Monnink J.P.
        • et al.
        SDHAF2 (PGL2-SDH5) and hereditary head and neck paraganglioma.
        Clin Cancer Res. 2011; 17: 247-254